Table 1.
Baseline characteristics of the 122 patients with stage III NSCLC treated with neoadjuvant chemotherapy and univariate analysis of factors possibly affecting the survival.
| OS |
|||||
|---|---|---|---|---|---|
| Characteristic | Number (%) | DSSp-value* | DFSp- value* | p- value* | 5 y (%) |
| Sex | |||||
| Male | 99 (81%) | 0.38 | 0.30 | 0.27 | 27.9 |
| Female | 23 (19%) | 42.4 | |||
| Age (years) | 1 | 0.64 | 0.26 | ||
| Median [IQR] | 58 [51.8–66.0] | ||||
| ≤58 | 30.9 | ||||
| >58 | 32.0 | ||||
| Smoking history | 0.65 | 0.70 | 0.54 | ||
| No | 17 (14%) | 29.6 | |||
| Yes | 105 (86%) | 32.3 | |||
| Median pack/year [IQR] | 40 [30–60] | ||||
| Symptoms | 0.80 | 0.60 | 0.29 | ||
| Yes | 84 (69%) | 28.4 | |||
| No | 38 (31%) | 27.9 | |||
| FEV1 (%) | 0.26 | 0.27 | 0.17 | ||
| Median [IQR] | 83 [71.2–96.7] | ||||
| ≤83 | 64 (52%) | 22.2 | |||
| >83 | 58 (48%) | 40.8 | |||
| Performance status | 0.37 | 0.79 | 0.62 | ||
| 0–1 | 92 (75%) | 31.58 | |||
| 2–3 | 30 (25%) | 29.18 | |||
| Comorbidity | 0.72 | 0.89 | 0.99 | ||
| No | 22 (18%) | 27.8 | |||
| Yes | 100 (82%) | 32.2 | |||
| Moderate | 79 | ||||
| Severe | 21 | ||||
| Side of the tumor | 0.57 | 0.64 | 0.56 | ||
| Left | 40 (33%) | 36.4 | |||
| Right | 82 (67%) | 28.2 | |||
| Size of the tumor (mm; imaging evaluation) | 0.26 | 0.37 | 0.21 | ||
| Median [IQR] | 50 [40–60] | 15.8 | |||
| ≤50 | 61 (50%) | 37.8 | |||
| >50 | 61 (50%) | ||||
| TNM stage before neoadjuvant chemotherapy§ | 0.61 | 0.51 | 0.86 | ||
| IIIA | 111 (91%) | 32 | |||
| IIIB | 11 (9%) | 20.2 | |||
| Drug combination (neoadjuvant chemotherapy) | 0.84 | 0.79 | 0.684 | ||
| Cisplatin+gemcitabine | 56 (46%) | 31 | |||
| Cisplatin+vinorelbine | 42 (34%) | 27 | |||
| Cisplatin+paclitaxel | 17 (14%) | 55.4 | |||
| Platinum salt+other | 7 (6%) | 34.3 | |||
| Number of cycles | 0.12 | 0.06 | 0.004 | ||
| ≤2 | 53 (44%) | 19.5 | |||
| >2 | 69 (56%) | 41.1 | |||
| Neoadjuvant radiotherapy | NA | NA | NA | ||
| Yes | 3 (2%) | NR | |||
| No | 119 (98%) | 31.3% | |||
| Clinical-specific response on the tumor | 0.00031 | 0.000098 | 0.00051 | ||
| Stable disease | 45 (37%) | 13.5 | |||
| Objective response | 77 (63%) | 39.9 | |||
| Clinical-specific response on the lymph node | 0.000033 | 0.0018 | 0.0009 | ||
| Stable disease | 44 (36%) | 14.8 | |||
| Objective response | 78 (64%) | 39.7 | |||
| Overall clinical response (T+N) | 0.00025 | 0.0032 | 0.00059 | ||
| Yes | 88 (72%) | 38.4 | |||
| No | 34 (28%) | 11.3 | |||
| Intervention | 0.051 | 0.26 | 0.025 | ||
| Lobectomy | 54 (44%) | 42.7 | |||
| Bilobectomy | 12 (10%) | NR | |||
| Pneumonectomy | 56 (46%) | 23.5 | |||
| Resection quality | 0.15 | 0.072 | 0.062 | ||
| R0 | 114 (93%) | 32.2 | |||
| R1–2 | 8 (7%) | NR | |||
| Histological type | 0.12 | 0.027 | 0.047 | ||
| Adenocarcinoma | 51 (42%) | 52.2 | |||
| Squamous cell carcinoma | 52 (43%) | 24.5 | |||
| Large cell carcinoma | 19 (15%) | 14.7 | |||
| Pathological downstaging (lymph nodes) | 0.0052 | 0.019 | 0.0041 | ||
| Yes (pN0–N1) | 51 (42%) | 41.4 | |||
| No (pN2) | 71 (58%) | 23.6 | |||
| Pathological downstaging (global) | 0.020 | 0.042 | 0.0068 | ||
| Yes | 42 (34%) | 37.5 | |||
| No | 80 (66%) | 27 | |||
| ypT | 30(24.5%) | 0.66 | 0.042 | 0.012 | 51.8 |
| T0–T1 | |||||
| T2–T4 | 92 (75.5%) | 25.7 | |||
| Pathological stage# | 0.0047 | 0.0098 | 0.016 | ||
| 0–I | 25 (21%) | 55.8 | |||
| II–IV | 97 (79%) | 25.7 | |||
| Percentage of viable cancer cells | 0.025 | 0.084 | 0.013 | ||
| 0–10% | 27 (22%) | 51.4 | |||
| >10% | 95 (78%) | 27.5 | |||
*
The log-rank test was used. To be able to conduct univariate analyses with a categorical variable, they were coded before analysis:
§
TNM stage before neoadjuvant chemotherapy: IIIA (T1N2 = 9; T2N2 = 84; T3N2 = 18); IIIB (T4N2 = 11).
#
TNM stage after neoadjuvant chemotherapy: 0 (T0N0 = 8); I (T1N0 = 11; T2N0 = 6); II (T0N1 = 1; T1N1 = 2; T2N1 = 3; T3N0 = 8); IIIA (T0N2 = 2; T1N2 = 6; T2N2 = 32; T3N1 = 7; T3N2 = 20); IIIB (T4N0 = 1; T4N1 = 10; T4N2 = 3); IV (T2N1M1 = 1; T3N2M1 = 1).
IQR, interquartile range; NA, not applicable; NR, not reached.Bold: Significant p values.